An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome

Abstract

Aim: The aim of this study was to evaluate new and current inflammatory markers in women with polycystic ovary syndrome (PCOS)and to clarify the role of these markers in the etiopathogenesis of PCOS.Material and Methods: This retrospective study included 97 women with PCOS and 124 body mass index-matched controls withoutPCOS. The parameters examined as new and current markers in both groups were the monocyte-to-high density lipoproteincholesterol (HDL-C) ratio, high sensitivity C-reactive protein/ albumin ratio, systemic immune-inflammation index, inflammatoryprognostic index, prognostic nutritional index, white blood cell count, mean platelet volume, platelet distribution width, plateletcrit,neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, triglycerides to HDL-C ratio and the lipid accumulation product index.Results: No significant difference was found between the PCOS and control group in respect of inflammatory markers. The age andfollicle-stimulating hormone values of PCOS patients were found to be lower than those of the control group. Luteinizing hormone,free androgen index, insulin and the homeostasis model assessment of insulin resistance values of PCOS patients were significantlyhigher than those of the control group.Conclusion: In terms of inflammatory parameters, no significant difference was determined between patients with PCOS and thecontrol group. Chronic inflammation may be multifactorial in PCOS and there is a need for studies with larger sample sizes to be ableto explain the exact role of inflammatory markers in PCOS etiology